MOVIDA1-Ter: MOVIDA 1 Ter - Evaluation of the Cobas® Plasma Separation Card in the Field in Vietnam

Sponsor
Institut Pasteur (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT04794725
Collaborator
National Institute of Hygiene and Epidemiology - Vietnam (NIHE) (Other)
250
1
12

Study Details

Study Description

Brief Summary

In low- and middle-income countries, viral load (VL) monitoring of patients living with HIV and followed on antiretroviral therapy (ART) in remote settings is still scarce. Barriers to VL monitoring are essentially the limited access to a laboratory able to perform this measurement, its cost, as well as the lack of human and material resources. Blood sampling using dried blood spots (DBS), which has been validated and is immediately available, could overcome these barriers. With DBS, transfer and conservation of samples are simplified enabling access to VL monitoring to patients seeking care in sites far from laboratory facilities. Use of DBS also offers the advantage not to require extensive investments.

To guide decision makers in the implementation of strategies to scale-up HIV VL monitoring in remote settings, field evaluations of DBS in routine conditions are needed. It is in this context that we propose this field evaluation of the Cobas® plasma separation card in Vietnam

Condition or Disease Intervention/Treatment Phase
  • Procedure: Blood sampling
N/A

Detailed Description

In Vietnam, in 2018, HIV prevalence was estimated at 0.3% among adults and the estimated proportion of PLHIV on ART was 65%, however the HIV epidemic is essentially concentrated in people who inject drugs, men who have sex with men and sex workers.

As of today, routine HIV VL monitoring is not yet available in remote settings in Vietnam. Despite an initiative we conducted and that documented the feasibility of DBS use in remote settings, and although no genuine roll-out of POC machines is yet observed in the field, the Ministry of Health of Vietnam has not yet decided to scale-up HIV VL monitoring using DBS. More field evaluations are needed to convince the Ministry of Health that DBS can effectively be used to scale-up HIV VL monitoring.

The aim of the present study is to evaluate the sensitivity and specificity of HIV VL measurement using the cobas® plasma separation card (PSC) against plasma at the threshold of 1000 copies/mL (threshold currently used to define failure in Vietnam, following the WHO guidelines).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
250 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Monitoring Of Viral Load In Decentralised Area 1 Ter - Evaluation of the Cobas® Plasma Separation Card in the Field in Vietnam
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Sep 1, 2023
Anticipated Study Completion Date :
Sep 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Other: Blood Sampling

blood samples from venepuncture (10mL)

Procedure: Blood sampling
blood samples from venepuncture (10mL)

Outcome Measures

Primary Outcome Measures

  1. Quantification of HIV RNA on DBS compared to plasma as gold standard [up to 4 weeks]

    sensitivity and specificity of the Cobas® PSC against plasma (as gold standard) at to identify virological failure (HIV VL ≥1000 copies/mL)

Secondary Outcome Measures

  1. Correlation between HIV RNA VL measured on DBS and on plasma [up to 4 weeks]

    Comparison of quantitative HIV VL results obtained on plasma and when using the cobas® PSC

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • ≥18 years of age

  • HIV-1 infected adults

  • Willing to participate to the study by giving his/her consent

Exclusion Criteria:
  • None

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Institut Pasteur
  • National Institute of Hygiene and Epidemiology - Vietnam (NIHE)

Investigators

  • Study Director: Yoann MADEC, PhD, Institut Pasteur
  • Principal Investigator: Tuan Anh NGUYEN, MD, PhD, National Institute of Hygiene and Epidemiology, Vietnam

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Institut Pasteur
ClinicalTrials.gov Identifier:
NCT04794725
Other Study ID Numbers:
  • 2020-067
First Posted:
Mar 12, 2021
Last Update Posted:
Aug 3, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Institut Pasteur
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 3, 2022